Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.

We report the findings and outputs of an international expert opinion process to develop a definition of early Crohn's disease (CD) that could be used in future disease-modification trials. Nineteen experts on inflammatory bowel diseases held an international expert opinion meeting to discuss a...

Full description

Bibliographic Details
Main Authors:	Peyrin-Biroulet, L, Billioud, V, D'Haens, G, Panaccione, R, Feagan, B, Panés, J, Danese, S, Schreiber, S, Ogata, H, Hibi, T, Higgins, P, Beaugerie, L, Chowers, Y, Louis, E, Steinwurz, F, Reinisch, W, Rutgeerts, P, Colombel, J, Travis, S, Sandborn, W
Format:	Journal article
Language:	English
Published:	2012

Similar Items

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
by: Sandborn, W, et al.
Published: (2016)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
by: Danese, S, et al.
Published: (2015)

Development of the Crohn's disease digestive damage score, the Lemann score.
by: Pariente, B, et al.
Published: (2011)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
by: Reinisch, W, et al.
Published: (2018)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
by: D'Haens, G, et al.
Published: (2009)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
by: Khanna, R, et al.
Published: (2023)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
by: Colombel, J, et al.
Published: (2017)

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.
by: Jairath, V, et al.
Published: (2016)

Evolving concepts in phases I and II drug development for Crohn's Disease
by: Jairath, V, et al.
Published: (2016)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
by: Panaccione, R, et al.
Published: (2019)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
by: Remo Panaccione, et al.
Published: (2015-12-01)

Development of an index to define overall disease severity in IBD
by: Siegel, C, et al.
Published: (2016)

Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?
by: Ferdinando D’Amico, et al.
Published: (2020-06-01)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
by: Gottlieb, K, et al.
Published: (2015)

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
by: Peyrin-Biroulet, L, et al.
Published: (2015)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
by: Mahadevan, U, et al.
Published: (2011)

Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
by: Yzet, C, et al.
Published: (2019)

Lymphoma risk and overall safety profile of Adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid
by: D'Haens, G, et al.
Published: (2018)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
by: Gasche, C, et al.
Published: (2000)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
by: D'Haens, G, et al.
Published: (2011)

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
by: Travis, S, et al.
Published: (2006)

Taking Crohn’s Disease Personally
by: Yehuda Chowers
Published: (2013-04-01)

Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme.
by: Ferrante, M, et al.
Published: (2012)

American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
by: Clark, M, et al.
Published: (2007)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
by: Miquel Marquès Camí, et al.
Published: (2021-01-01)

The Role of IL-23 Inhibitors in Crohn’s Disease
by: Jacopo Fanizza, et al.
Published: (2023-12-01)

Closure of enterovesical fistula in Crohn’s disease with infliximab: case report
by: Flávio Steinwurz
Published: (2003-03-01)

Estudo evolutivo de fístulas na doença de Crohn A follow-up study of fistulae in Crohn's disease
by: Flavio STEINWURZ
Published: (1999-12-01)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
by: Ferdinando D'Amico, et al.
Published: (2020-07-01)

Can we change the natural course of inflammatory bowel disease?
by: Catherine Le Berre, et al.
Published: (2023-04-01)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
by: Jairath, V, et al.
Published: (2016)

Review article: defining remission in ulcerative colitis.
by: Travis, S, et al.
Published: (2011)

Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD)
by: Federica Furfaro, et al.
Published: (2022-07-01)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
by: Van Assche, G, et al.
Published: (2011)

Preventing disability in inflammatory bowel disease
by: Patrick B. Allen, et al.
Published: (2017-11-01)

Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.
by: Sandborn, W, et al.
Published: (2001)

Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
by: Laurent Peyrin‐Biroulet, et al.
Published: (2024-03-01)

Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort studyResearch in context
by: Mariangela Allocca, et al.
Published: (2024-05-01)

Ulcerative Colitis: Shifting Sands
by: Geert R. A. M. D’Haens, et al.
Published: (2019-03-01)

Review: Efficacy and safety of adalimumab in Crohn's disease
by: Gary R. Lichtenstein, et al.
Published: (2008-07-01)